Computed tomography-based sarcopenia and pancreatic cancer: Prognostic value and variability based on different...

Area of Science:

• Oncology
• Radiology
• Medical Imaging

Background:

• Sarcopenia, characterized by loss of skeletal muscle mass, is increasingly recognized as a significant factor in cancer prognosis.
• Computed Tomography (CT) is commonly used in cancer staging and can also assess body composition, including muscle mass.

Purpose of the Study:

• To investigate the prognostic value of CT-determined sarcopenia on overall survival in patients diagnosed with pancreatic cancer.
• To analyze the variability of prognostic outcomes based on different sarcopenia assessment criteria found in existing literature.

Main Methods:

• Retrospective observational study of patients with histologically confirmed pancreatic adenocarcinoma.
• Utilized artificial intelligence (Comp2Comp, TotalSegmentator) for automated body composition analysis from CT scans.
• Defined sarcopenia using established criteria (Prado et al.) and compared with alternative thresholds, employing survival analyses (Kaplan-Meier, Cox regression).

Main Results:

• Included 71 patients with a median overall survival of 10 months.
• Prevalence of sarcopenia varied significantly (5.6%–70.4%) based on criteria, with Prado et al.'s criteria identifying 59.2%.
• Sarcopenia by Prado et al. criteria was linked to reduced survival (cHR: 2.03), while other criteria showed inconsistent prognostic value (cHR range: non-significant to 6.05).

Conclusions:

• CT-determined sarcopenia serves as a prognostic indicator for overall survival in pancreatic cancer.
• Significant heterogeneity exists in sarcopenia assessment methods and thresholds, necessitating standardization for reliable clinical application.